Accelerating Cancer Therapeutics (ACT) is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to entrepreneurs and the pharmaceutical industry to advance novel cancer therapeutics from the lab towards the path of commercialization and clinical implementation. The program will provide education, mentorship and funding to help academic translational research projects move beyond the “valley of death” in therapeutic development and reach significant milestones. A key goal of this program is to accelerate translation of novel medical discoveries in cancer from the lab to the clinic by positioning the technology for commercialization.

The Translational Therapeutics Accelerator (TRx) is a program designed to leverage Columbia’s proficiency in drug discovery and provide access to funding and industry experts with the goal of advancing novel therapeutics from the lab towards the path of commercialization. The TRx Resource provides education (10‐session boot camp), mentorship (drug development team) and funding (Pilot Award) to help translational researchers reach a point of value inflection. While indication agnostic, the educational aspect of the program provides a special focus on orphan/rare diseases.

The Columbia Biomedical Accelerator aims to catalyze the advancement of biomedical technologies by providing funding, education, resources and mentorship to interdisciplinary teams of clinicians, engineers, scientists and students working to develop solutions to clinical unmet needs, with the ultimate goal of bringing innovative research out of the lab to benefit society. Project support is expected to serve as a bridge to commercial investment, with awards granted to perform specific tasks needed to validate a commercial hypothesis (vs. a scientific hypothesis).